The power of precision.
For every cancer patient.
Today.
Founded in Copenhagen
as a spin-out from the Carlsberg Research Center, aiming to enhance patient responses to cancer treatments through functional drug sensitivity testing.
Established 2cureX GmbH
a German affiliate, to expand its presence in Europe.
Listed on the Nasdaq First North Growth Market
marking its transition to a publicly traded
company
Launched IndiTreat®
the first CE IVD-marked drug sensitivity test using 3D tumoroids, providing precision in treatment decisions for cancer patients.
Announced management changes
and a strategic focus on making IndiTreat® testing available in hospitals worldwide.
Reported severe financial challenges
indicating insufficient working capital to continue planned operations beyond the second quarter of 2024. 2cureX
Delisting from Nasdaq
Decided to apply for delisting from Nasdaq First North Growth Market due to financial constraints.
Issued 7,500,000 new shares
to an investment consortium led by the Kinled Group and secured a €3 million loan to support growth in Functional Precision Oncology.
Hosted a webcast and Q&A
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Appointed Mangold Fondkommission AB
as a liquidity provider for the company's shares, aiming to enhance share liquidity and stability.
Appointed Mangold Fondkommision AB
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Next investment
2cureX
The power of precision.
For every cancer patient.
Today.
Founded in Copenhagen
as a spin-out from the Carlsberg Research Center, aiming to enhance patient responses to cancer treatments through functional drug sensitivity testing.
Established 2cureX GmbH
a German affiliate, to expand its presence in Europe.
Listed on the Nasdaq First North Growth Market
marking its transition to a publicly traded
company
Launched IndiTreat®
the first CE IVD-marked drug sensitivity test using 3D tumoroids, providing precision in treatment decisions for cancer patients.
Announced management changes
and a strategic focus on making IndiTreat® testing available in hospitals worldwide.
Reported severe financial challenges
indicating insufficient working capital to continue planned operations beyond the second quarter of 2024. 2cureX
Delisting from Nasdaq
Decided to apply for delisting from Nasdaq First North Growth Market due to financial constraints.
Issued 7,500,000 new shares
to an investment consortium led by the Kinled Group and secured a €3 million loan to support growth in Functional Precision Oncology.
Hosted a webcast and Q&A
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Appointed Mangold Fondkommission AB
as a liquidity provider for the company's shares, aiming to enhance share liquidity and stability.
Appointed Mangold Fondkommision AB
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Next investment
2cureX
The power of precision.
For every cancer patient.
Today.
Founded in Copenhagen
as a spin-out from the Carlsberg Research Center, aiming to enhance patient responses to cancer treatments through functional drug sensitivity testing.
Established 2cureX GmbH
a German affiliate, to expand its presence in Europe.
Listed on the Nasdaq First North Growth Market
marking its transition to a publicly traded
company
Launched IndiTreat®
The first CE IVD-marked drug sensitivity test using 3D tumoroids, providing precision in treatment decisions for cancer patients.
Announced management changes
and a strategic focus on making IndiTreat® testing available in hospitals worldwide.
Reported severe financial challenges
indicating insufficient working capital to continue planned operations beyond the second quarter of 2024. 2cureX
Delisting from Nasdaq
Decided to apply for delisting from Nasdaq First North Growth Market due to financial constraints.
Issued 7,500,000 new shares
to an investment consortium led by the Kinled Group and secured a €3 million loan to support growth in Functional Precision Oncology.
Hosted a webcast and Q&A
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Appointed Mangold Fondkommission AB
as a liquidity provider for the company's shares, aiming to enhance share liquidity and stability.
Appointed Mangold Fondkommision AB
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Next investment
Menu
Close
The power of precision.
For every cancer patient.
Today.
Founded in Copenhagen
as a spin-out from the Carlsberg Research Center, aiming to enhance patient responses to cancer treatments through functional drug sensitivity testing.
Established 2cureX GmbH
a German affiliate, to expand its presence in Europe.
Listed on the Nasdaq First North Growth Market
marking its transition to a publicly traded
company
Launched IndiTreat®
the first CE IVD-marked drug sensitivity test using 3D tumoroids, providing precision in treatment decisions for cancer patients.
Announced management changes
and a strategic focus on making IndiTreat® testing available in hospitals worldwide.
Reported severe financial challenges
indicating insufficient working capital to continue planned operations beyond the second quarter of 2024. 2cureX
Delisting from Nasdaq
Decided to apply for delisting from Nasdaq First North Growth Market due to financial constraints.
Issued 7,500,000 new shares
to an investment consortium led by the Kinled Group and secured a €3 million loan to support growth in Functional Precision Oncology.
Hosted a webcast and Q&A
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Appointed Mangold Fondkommission AB
as a liquidity provider for the company's shares, aiming to enhance share liquidity and stability.
Appointed Mangold Fondkommision AB
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Next investment
2cureX
The power of precision.
For every cancer patient.
Today.
Founded in Copenhagen
as a spin-out from the Carlsberg Research Center, aiming to enhance patient responses to cancer treatments through functional drug sensitivity testing.
Established 2cureX GmbH
a German affiliate, to expand its presence in Europe.
Listed on the Nasdaq First North Growth Market
marking its transition to a publicly traded
company
Launched IndiTreat®
the first CE IVD-marked drug sensitivity test using 3D tumoroids, providing precision in treatment decisions for cancer patients.
Announced management changes
and a strategic focus on making IndiTreat® testing available in hospitals worldwide.
Reported severe financial challenges
indicating insufficient working capital to continue planned operations beyond the second quarter of 2024. 2cureX
Delisting from Nasdaq
Decided to apply for delisting from Nasdaq First North Growth Market due to financial constraints.
Issued 7,500,000 new shares
to an investment consortium led by the Kinled Group and secured a €3 million loan to support growth in Functional Precision Oncology.
Hosted a webcast and Q&A
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Appointed Mangold Fondkommission AB
as a liquidity provider for the company's shares, aiming to enhance share liquidity and stability.
Appointed Mangold Fondkommision AB
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Next investment
2cureX
The power of precision.
For every cancer patient.
Today.
Founded in Copenhagen
as a spin-out from the Carlsberg Research Center, aiming to enhance patient responses to cancer treatments through functional drug sensitivity testing.
Established 2cureX GmbH
a German affiliate, to expand its presence in Europe.
Listed on the Nasdaq First North Growth Market
marking its transition to a publicly traded
company
Launched IndiTreat®
The first CE IVD-marked drug sensitivity test using 3D tumoroids, providing precision in treatment decisions for cancer patients.
Announced management changes
and a strategic focus on making IndiTreat® testing available in hospitals worldwide.
Reported severe financial challenges
indicating insufficient working capital to continue planned operations beyond the second quarter of 2024. 2cureX
Delisting from Nasdaq
Decided to apply for delisting from Nasdaq First North Growth Market due to financial constraints.
Issued 7,500,000 new shares
to an investment consortium led by the Kinled Group and secured a €3 million loan to support growth in Functional Precision Oncology.
Hosted a webcast and Q&A
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Appointed Mangold Fondkommission AB
as a liquidity provider for the company's shares, aiming to enhance share liquidity and stability.
Appointed Mangold Fondkommision AB
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Next investment
Menu
Close
The power of precision.
For every cancer patient.
Today.
Founded in Copenhagen
as a spin-out from the Carlsberg Research Center, aiming to enhance patient responses to cancer treatments through functional drug sensitivity testing.
Established 2cureX GmbH
a German affiliate, to expand its presence in Europe.
Listed on the Nasdaq First North Growth Market
marking its transition to a publicly traded
company
Launched IndiTreat®
the first CE IVD-marked drug sensitivity test using 3D tumoroids, providing precision in treatment decisions for cancer patients.
Announced management changes
and a strategic focus on making IndiTreat® testing available in hospitals worldwide.
Reported severe financial challenges
indicating insufficient working capital to continue planned operations beyond the second quarter of 2024. 2cureX
Delisting from Nasdaq
Decided to apply for delisting from Nasdaq First North Growth Market due to financial constraints.
Issued 7,500,000 new shares
to an investment consortium led by the Kinled Group and secured a €3 million loan to support growth in Functional Precision Oncology.
Hosted a webcast and Q&A
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Appointed Mangold Fondkommission AB
as a liquidity provider for the company's shares, aiming to enhance share liquidity and stability.
Appointed Mangold Fondkommision AB
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Next investment
2cureX
The power of precision.
For every cancer patient.
Today.
Founded in Copenhagen
as a spin-out from the Carlsberg Research Center, aiming to enhance patient responses to cancer treatments through functional drug sensitivity testing.
Established 2cureX GmbH
a German affiliate, to expand its presence in Europe.
Listed on the Nasdaq First North Growth Market
marking its transition to a publicly traded
company
Launched IndiTreat®
the first CE IVD-marked drug sensitivity test using 3D tumoroids, providing precision in treatment decisions for cancer patients.
Announced management changes
and a strategic focus on making IndiTreat® testing available in hospitals worldwide.
Reported severe financial challenges
indicating insufficient working capital to continue planned operations beyond the second quarter of 2024. 2cureX
Delisting from Nasdaq
Decided to apply for delisting from Nasdaq First North Growth Market due to financial constraints.
Issued 7,500,000 new shares
to an investment consortium led by the Kinled Group and secured a €3 million loan to support growth in Functional Precision Oncology.
Hosted a webcast and Q&A
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Appointed Mangold Fondkommission AB
as a liquidity provider for the company's shares, aiming to enhance share liquidity and stability.
Appointed Mangold Fondkommision AB
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Next investment
2cureX
The power of precision.
For every cancer patient.
Today.
Founded in Copenhagen
as a spin-out from the Carlsberg Research Center, aiming to enhance patient responses to cancer treatments through functional drug sensitivity testing.
Established 2cureX GmbH
a German affiliate, to expand its presence in Europe.
Listed on the Nasdaq First North Growth Market
marking its transition to a publicly traded
company
Launched IndiTreat®
The first CE IVD-marked drug sensitivity test using 3D tumoroids, providing precision in treatment decisions for cancer patients.
Announced management changes
and a strategic focus on making IndiTreat® testing available in hospitals worldwide.
Reported severe financial challenges
indicating insufficient working capital to continue planned operations beyond the second quarter of 2024. 2cureX
Delisting from Nasdaq
Decided to apply for delisting from Nasdaq First North Growth Market due to financial constraints.
Issued 7,500,000 new shares
to an investment consortium led by the Kinled Group and secured a €3 million loan to support growth in Functional Precision Oncology.
Hosted a webcast and Q&A
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Appointed Mangold Fondkommission AB
as a liquidity provider for the company's shares, aiming to enhance share liquidity and stability.
Appointed Mangold Fondkommision AB
with the Executive Management and Board of Directors to discuss the company's status and future outlook.
Next investment